Current Report Filing (8-k)
April 04 2017 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 3, 2017
CELGENE
CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-34912
|
|
22-2711928
|
(State or other Jurisdiction
of
Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification
No.
)
|
86 Morris Avenue, Summit, New Jersey
|
|
07901
|
(Address of Principal
Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(908) 673-9000
|
(Former
name or former address if changed since last report.)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On April 3, 2017, Celgene Corporation announced it
has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application
(ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture and market a generic version
of POMALYST
®
(pomalidomide) 1 mg, 2 mg, 3 mg and 4 mg in the United States.
The Notice Letter contains Paragraph IV certifications
against certain of Celgene’s patents related to POMALYST
®
. Celgene intends to vigorously defend its extensive
intellectual property rights related to POMALYST
®
.
Attached hereto and incorporated herein by reference
as Exhibit 99.1 is the Press Release announcement.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
Exhibit 99.1 — Press Release
dated April 3, 2017
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release dated April 3, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
|
Date: April 3, 2017
|
|
|
|
|
|
|
By:
|
Peter N. Kellogg
|
|
Name: Peter N. Kellogg
|
|
Title: Executive Vice President and Chief
Financial Officer
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024